SRNE - Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues
- Sorrento Therapeutics' revenues are up 33% year-on-year.
- The Company recently received orders for its COVISTIX.
- Sorrento Therapeutics has acquired Fortune Bioscience and Virex Health.
For further details see:
Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues